|
|
|
|
Subchronic and Chronic Toxicity
(Other than Carcinogenicity) |
|
Subchronic [RfD]: (see comment) |
5E-4 mg/kg/day |
|
Uncertainty Factor: |
300 |
|
Route: |
Oral: diet |
|
Target Organ / Critical Effect: |
Liver / Increased weight |
|
Species |
Effect Level |
Dose |
Experiment Length |
Rat |
NOEL |
0.15 mg/kg/day |
2 years |
|
References |
1955 | Velsicol Chemical Corp. 1955. MRID No. 00062599. Available from EPA. Write to FOI, EPA, Washington, DC 20460. |
1987 | U.S. EPA. 1987. RfD/RfC Work Group. |
|
Subchronic [RfD] Comments: |
The chronic oral RfD was adopted as the subchronic oral [RfD]. |
|
|
|
|
Carcinogenicity |
|
Inhalation [Slope Factor]: (see comment) | 4.5E+0 (mg/kg/day)-1 |
|
|
Route: |
Oral: diet |
|
Target Organ / Cancer: |
Liver / Carcinoma |
|
Species |
EPA Group |
|
Mouse |
IRIS |
|
|
References |
1965 | Davis K. 1965. Pathology report on mice fed Aldrin, Dieldrin, Heptachlor, and Heptachlor Epoxide for two years. Internal FDA memorandum to Dr. A.J. Lehman, July 19. |
1977 | NCI (National Cancer Institute). 1977. Bioassay of Heptachlor for possible carcinogenicity. NCI Carcinogenesis Tech Rep Ser No. 9, DHEW No. (NIH) 77-809. |
1976 | Epstein, S.S. 1976. Carcinogenicity of Heptachlor and Chlordane. Sci Total Environ. 6: 103-154. |
1977 | Reuber, M.D. 1977. Histopathology of carcinomas of the liver in mice ingesting Heptachlor or Heptachlor Epoxide. Exp Cell Biol. 45: 147-157. |
1986 | U.S. EPA. 1986. Carcinogenicity assessment of Chlordane and Heptachlor/Heptachlor Epoxide. Prepared by the Office of Health and Environmental Assessment, Carcinogen Assessment Group, Washington, DC. |
1987 | U.S. EPA. 1987. Health effects assessment for Heptachlor. Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Emergency and Remedial Response, Washington, DC. |
1987 | U.S. EPA. 1987. Carcinogen Risk Assessment Verification Endeavor (CRAVE) Work Group. |
|
Inhalation Slope Comment: |
Based on route to route extrapolation. See Appendix A-II, Dose Conversions on HEAST. |
|